Nerve Growth Factor Receptor antibody (NGFR) is a useful immunohistochemical marker, when used in conjunction with the S100 antibody, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas, which are often negative for other melanocytic markers (HMB45, MART-1/Melan-A). Studies have shown that NGFR is expressed on Schwann cells, neuronal axons and perineural cells, as well as tumors derived from those cells, to include malignant peripheral nerve sheath tumors, Schwannomas, granular cell tumors and neurofibromas.
|Download Data Sheet
|Download RUO Data Sheet for International
|Download SDS Sheet
Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.
1. Kaplan DR, Miller FD. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol. 1997 Apr;9(2):213-21.
2. Bunone G, et al. Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells. Oncogene. 1997 Mar 27;14(12):1463-70.
3. Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol. 1996 Jun;23(3):205-10.
4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
5. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.